Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …

Cholangiocarcinoma is characterized by a poor prognosis with limited treatment and
management options. Chemotherapy using gemcitabine with cisplatin is the only available …

PURPOSE To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with
previously treated human epidermal growth factor receptor 2–positive (HER2+) metastatic …

Simple Summary Intrahepatic cholangiocarcinoma is the second most common primary liver
malignancy after hepatocellular carcinoma and accounts for 20% of biliary tract cancers. The …

Cholangiocarcinoma (CCA) is a malignant neoplasm arising in the epithelium of the biliary
tract. It represents the second most common primary liver cancer in the world, after …

Gastrointestinal (GI) cancer constitutes a highly lethal entity among malignancies in the last
decades and is still a major challenge for cancer therapeutic options. Despite the current …

Objective To analyze the effectiveness of combining immune checkpoint inhibitors (ICIs) with
first-line therapy in patients with advanced biliary tract cancer (BTC) and explore the …

Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant
tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the …

Following the practice-changing results observed in several hematological and solid tumors,
immunotherapy with immune checkpoint inhibitors (ICIs) has been tested in …

Purpose: The present study aims to evaluate the effect of prognostic nutrition index (PNI) on
the response and prognosis of patients with metastatic biliary tract cancer (BTC) patients …